Ayurvedic therapies, including herbal medicines and Mustadi Yapana Basti, tested for their effectiveness in improving kidney health in chronic kidney disease: A comparative study.

A Randomized Comparative Clinical Study on the Add-on Efficacy of Gokshura Kwatha with Shuddha Shilajit and Shuddha Guggulu over Varunadi Kwatha and Gokshuradi Guggulu, along with Mustadi Yapana Basti in Chronic Kidney Disease - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/098991

Enrollment

104

Registered

2025-12-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N184- Chronic kidney disease, stage 4 (severe)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Participants of either gender, aged twenty one to sixty five years, with a confirmed diagnosis of Chronic Kidney Disease up to Stage or Grade Four as per KDIGO criteria with estimated glomerular filtration rate greater than fifteen and smaller than sixty millilitres per minute per one point seven three square metre. Only clinically stable Grade Four patients who were not requiring immediate Renal Replacement Therapy at the time of enrolment. Participants who were willing to provide written informed consent. Participants who were not registered in any other research project in the last twelve weeks.

Exclusion criteria

Exclusion criteria: Participants with active Tuberculosis, malignancy, or any other uncontrolled systemic illness. Pregnant or lactating women. Participants with severe anaemia with haemoglobin smaller than six grams per decilitre. Participants with uncontrolled Diabetes with haemoglobin A one C greater than nine or uncontrolled Hypertension with blood pressure greater than one hundred sixty by one hundred millimetres of mercury. Participants with HIV associated nephropathy or transplant allograft failure. Known cases of renal artery stenosis or renal neoplasm. Participants with a history of kidney transplantation. Participants with congenital renal diseases such as Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Congenital Nephrotic Syndrome of Finnish type, Alport Syndrome, Fabry Disease, and Juvenile Nephronophthisis. Participants with acute kidney injury, rapidly progressive renal failure, or any complications necessitating immediate Renal Replacement Therapy.

Design outcomes

Primary

Measure	Time frame
Improvement in estimated Glomerular Filtration Rate (eGFR) from baseline to end of treatment.Timepoint: 0th, 9th, 31st and 61st days.	—

Secondary

Measure	Time frame
1.Improvement in routine laboratory investigations. 2.Improvement in clinical signs & symptoms of CKD 3.Improvement in Quality of Life assessed using KDQOL-36 questionnaire.Timepoint: 0th, 9th, 31st & 61st days.	—

Countries

India

Contacts

Public ContactDr Raja Ram Mahto

All India Institute of Ayurveda, New Delhi.

drrkyadava@gmail.com9412148437

Outcome results